Articles

Demographic shift steers Lilly’s Asian operations

China remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic growth.

Read More

SPECIAL REPORT: Indiana companies charge into China

With economic growth in the United States sluggish, Indiana companies are joining the race to capitalize on the fast-growing Chinese economy—even as hundreds of millions of Chinese move into the middle class and adopt a Western-style thirst for goods and services.

Read More

Hospitals’ finances improve somewhat in 2010

It was a good but not great year financially for three of the four largest hospital systems operating in the Indianapolis area last year—and hospital analysts are expecting several head winds to continue.

Read More

Self-funded plans draw small-firm interest

In the face of new health reform restrictions, expect more small employers to opt for self-funded health benefits, concludes a report this week from Indianapolis-based United Benefit Advisors.

Read More

Drugmakers call off animal-health deal, possible asset sale

Drugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling with regulators for a year over potential divestitures.
Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies considered selling.

Read More

Research jobs could flow from Purdue quad

Purdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers who might well have left the state for either coast.

Read More

PROXY CORNER: Eli Lilly and Co.

Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.

Read More

Lechleiter: After the deluge, we’ll be fine

Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.

Read More

Dow Agro thinks it has a winner

The Indianapolis-based company released more details this month about its Enlist Weed Control System, which would genetically modify corn, soybeans and cotton to be resistant to one of the most common weedkillers.

Read More

Lilly agrees to buy European animal health company

Elanco, the animal health division of Eli Lilly and Co., has agreed to acquire Jannsen Animal Health, a subsidiary of New Jersey-based Johnson & Johnson, pending regulatory approval. Financial terms of the deal were not disclosed.

Read More